Fig. 1From: The effect of adding real-world evidence to regulatory submissions on the breadth of population indicated for rare disease medicine treatment by the European Medicines AgencyThe medicine adoption model: PH − (non-pharmaceutical company stakeholder groups); PH + (pharmaceutical company stakeholder groups)Back to article page